Loading ...
Sorry, an error occurred while loading the content.

Genta's G3139 News Release

Expand Messages
    Greetings, Genta s G3139 is one we have been following for a few months now. Here is a press release from today. -Ben(KIA) ... Wednesday April 1, 8:35 am
    Message 1 of 1 , Apr 1, 1998
    • 0 Attachment
      Genta's G3139 is one we have been following for a few months now. Here
      is a press release from today.
      Wednesday April 1, 8:35 am Eastern Time

      Company Press Release

      Genta Announces Issue of Patent for Lead Antisense Compound
      That Targets the Bcl-2 Gene, Implicated in Prostate and Other

      SAN DIEGO--(BUSINESS WIRE)--April 1, 1998--Genta Incorporated
      (Nasdaq: GNTA - news) today announced that it has received notification
      from the U.S. Patent and Trademark Office that a patent has been
      issued for Genta's lead antisense compound, G3139, which is under
      development as a potential anticancer therapeutic. The patent provides
      protection for the composition of G3139 and its analogues.

      ``The protection this patent provides will aid in our continued development of
      G3139 as a highly promising therapeutic for a variety of cancers,'' stated
      Kenneth G. Kasses, President and Chief Executive Officer of

      As an antisense compound, G3139 is designed to act toward a specific
      gene and prevent it from triggering the production of disease-related protein.
      G3139's target, the bcl-2 gene, interferes in the normal mortality of cells
      (apoptosis) and has been implicated in prostate cancer, non-Hodgkin's
      lymphoma, melanoma, breast and other cancers.

      Recent findings on G3139 were reported in the February 1998 issue of
      Nature Medicine, a leading scientific peer-reviewed journal, concerning the
      effectiveness of the compound as a ``chemosensitizer'' that causes tumors
      to lose an acquired immunity to chemotherapy. In work conducted at the
      University of Vienna that modeled human melanoma, researchers showed
      that pre-treating laboratory mice with G3139 significantly increased the
      effectiveness of dacarbazine (DTIC), the most widely used
      chemotherapeutic agent in melanoma. The article reported that in 10 out of
      13 animals so treated, cancerous tumors were completely eliminated. The
      article also noted that, in a separate experiment, G3139 used alone had a
      significantly greater effect in reducing tumor growth than did the three
      control treatments.

      In December 1997, Genta announced the start of a Phase I/IIa clinical trial
      of G3139 at New York City's Memorial Sloan-Kettering Cancer Center to
      evaluate the compound against prostate cancer. In addition, a
      Phase I/IIa study of G3139 is now nearing completion at the Royal Marsden
      Hospital in London to study the compound's effect on non-Hodgkin's

      Genta plans to initiate other pre-clinical and clinical studies this year to
      evaluate the safety and efficacy of G3139 in other cancers.

      Genta Incorporated (Nasdaq: GNTA - news) is a biopharmaceutical
      company whose strategy consists of building a product and technology
      portfolio that represents varying degrees of development risk and market
      potential, including Anticode(tm) (antisense) products intended to treat
      cancer at its genetic source, oral controlled-release drugs and other
      genomics opportunities.

      The statements contained in this press release that are not historical are
      forward-looking statements within the meaning of Section 27A of the
      Securities Act of 1933, as amended, and Section 21E of the Securities and
      Exchange Act of 1934, as amended, including statements regarding the
      expectations, beliefs, intentions or strategies regarding the future. Without
      limiting the foregoing, the words ``anticipates,'' ``believes,'' ``expects,''
      ``intends,'' ``may'' and ``plans'' and similar expressions are intended to identify
      forward-looking statements. The Company intends that all forward-looking
      statements be subject to the safe harbor provisions of the Private
      Securities Litigation Reform Act of 1995. These forward-looking statements
      reflect the Company's views as of the date they are made with respect to
      future events, but are subject to many risks and uncertainties, which
      could cause the actual results of the Company to differ materially from any
      future results expressed or implied by such forward-looking statements,
      including the following: the results obtained in pre-clinical studies may not be
      indicative of results that will be obtained in clinical trials; all of Genta's
      potential products are at an early stage of development; neither Genta nor,
      to its knowledge, any other company, has successfully completed human
      clinical trials of a product based on antisense technology; there can be no
      assurance that Genta will receive regulatory approvals to commence or
      continue clinical trials of product candidates or to market any products or
      that delays in completion of clinical trials as a result of delays in patient
      enrollment or other factors will not occur;
      and there can be no assurance that Genta will be able to obtain adequate
      funding to achieve its objectives. The Company does not undertake to
      update any forward-looking statements.


      Robinson Lerer & Montgomery
      Mary Ann Dunnell
    Your message has been successfully submitted and would be delivered to recipients shortly.